Revolo Biotherapeutics Presents New Data on ‘1805 at the American College of Rheumatology Convergence 2023 Annual Conference
2023-11-07
临床2期
Revolo Biotherapeutics Presents New Data on ‘1805 at the American College of Rheumatology Convergence 2023 Annual Conference
- New preclinical data further elucidate ‘1805’s mechanism of action in rheumatoid arthritis (RA) -
NEW ORLEANS and CAMBRIDGE, United Kingdom, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that new preclinical data on ‘1805 will be presented via two posters at the American College of Rheumatology Convergence 2023 Annual Conference, which is being held November 10–15 at the San Diego Convention Center in San Diego, CA.
“These preclinical data provide further insights into ‘1805’s differentiated mechanism of action,” said Jonathan Rigby, Revolo’s Chief Executive Officer. “While current RA treatments can in part ameliorate joint destruction, they are limited in the ability to prevent osteoclast-induced bone destruction. These results highlight the capacity of ‘1805 to ‘reset’ a number of metabolic pathways involved in bone resorption, thus addressing the progressive bone and joint destruction that is a hallmark symptom of RA. In addition, ‘1805 normalizes the expression of genes abnormally activated in cells from RA patients, such as those associated with inflammation. Altogether, the data support the clinical potential of ‘1805 and its further clinical evaluation. We look forward to initiating the Phase 2b clinical trial in the future.”
The principal investigator of the preclinical translational studies, Carl Goodyear, Professor of Translational Immunology at the University of Glasgow, UK, said, “The insights we have generated from this work, emphasize how powerful it is to harness physiological pathways aimed at regulating the immune system. Not only can ‘1805 fundamentally alter cell fate decisions within the innate immune compartment, but it has a unique ability to modulate cells from individuals whose compartment has been perturbed by systemic inflammation. We now need to take these studies to the next step and clearly demonstrate ‘1805’s clinical potential.”
Poster details:
Title:Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy DonorsPresenter:Yuriko Yamamura, Research Associate (Immunology & Infection), University of GlasgowAbstract #:2149Date/Time:November 14, 2023, 9:00 a.m. to 11:00 a.m. PTSession:Poster Session C
Presentation highlights:
Preclinical and clinical studies to date have demonstrated that ‘1805 interacts directly with monocytes, cells which play a key role in the initiation of inflammation and bone erosion in RA patients.
The effect of ‘1805 is selective towards “diseased” monocytes, as large gene expression changes were not observed in monocytes from healthy donors.
Presentation highlights:
Evaluation of gene expression showed that exposure of pre-osteoclasts to ‘1805 influenced the expression of multiple other genes involved in osteoclast differentiation.
Notably, ‘1805 influenced metabolic pathways critical for bone resorption, such as V-ATPases. This is particularly relevant, as antiresorptive drugs that inhibit V-ATPase activity have become an area of therapeutic development.
For more information, or to register for the conference: https://rheumatology.org/annual-meeting
About ‘1805
‘1805 is a modified analogue of the endogenous immune-regulatory binding immunoglobulin protein (BiP), a key player in immune function that resets the immune system for long-term disease remission. Its mechanism of action creates vast optionality across multiple indications and routes of administration.
About Revolo Biotherapeutics
Revolo Biotherapeutics is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, without the immune system suppression seen with current therapies. Its two drug candidates, ‘1805 and ‘1104, a protein and a peptide respectively, reset the immune system to prevent the chronic pro-inflammatory immune response that results in autoimmune or allergic disease. ‘1104 is a peptide derived from a natural immune-regulatory protein and has recently completed two Phase 2a clinical trials for patients with eosinophilic esophagitis (EoE) and allergic disease. The disease-agnostic mechanism of action of Revolo Biotherapeutic’s assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases.
For further information, please visit www.revolobio.com.
Company Contact
Marylyn Rigby, VP Investor Relations & Marketing
mrigby@revolobio.com
Media Contact
Monica Rouco Molina, Ph.D.
LifeSci Communications
+1-929-469-3850
mroucomolina@lifescicomms.com
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。